Takeda Ventures focuses on high-caliber therapeutic and platform based opportunities around the world.
Business Model:
Revenue: $30.4B
Employees: 10,001-999,999
Address: 1-1, Nihonbashi-Honcho 2-chome
City: Tokyo
State: tōkyō prefecture
Zip: 103-8668
Country: JP
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. We are based alongside Takeda’s R&a;D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance to entrepreneurs and early-stage companies driving concepts through clinical proof of concept. We also strive to forge active, collaborative interactions that result in synergies with Takeda&s;s considerable R&a;D resources. Our goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
5/2017 | BIOMx | Series A | 24M |
2/2010 | Domainex | Venture Round | - |
9/2014 | BioMotiv | Venture Round | 25M |
4/2018 | Crescendo Biologics | Series B | 0 |
6/2018 | StrideBio | Series A | 15.7M |
11/2017 | Outpost Medicine, LLC | Series A | 20M |
2/2021 | Xilio Therapeutics | Series C | 95M |
12/2016 | Hookipa Pharma | Series B | 10.7M |
1/2020 | Transine Therapeutics | Seed Round | - |
10/2018 | Bsense Bio Therapeutics | Seed Round | 405k |
5/2017 | OrphoMed | Series A | 39M |
10/2017 | Portal Instruments | Venture Round | 6M |
7/2012 | Juventas Therapeutics | Series B | 0 |
2/2019 | Hookipa Pharma | Series D | 37.4M |
2/2022 | Koneksa Health | Series C | 0 |
5/2021 | BridGene Biosciences | Series A | 0 |
6/2007 | Serenex | Series D | 0 |
12/2014 | Naurex | Series C | 0 |
10/2005 | Serenex | Series C | 30M |
3/2021 | Presage Biosciences | Convertible Note | 6M |
11/2022 | hC Bioscience | Series A | 0 |
1/2020 | Emendo Biotherapeutics | Series B | 61M |
5/2020 | Amwell | Series C | 0 |
11/2019 | Protekt Therapeutics | Venture Round | 4.1M |
12/2013 | VHSquared | Series A | - |
1/2020 | EvolveImmune Therapeutics | Venture Round | 17.5M |
10/2020 | Be Biopharma | Series A | 52M |
10/2019 | Arcellx | Series B | 0 |
9/2018 | Ramino Bio | Seed Round | - |
4/2021 | Adaptate Biotherapeutics | Series A | 18.2M |
2/2021 | Ensoma | Series A | 0 |
11/2013 | Hookipa Pharma | Series B | 27M |
8/2020 | ImmPACT Bio | Series A | 0 |
2/2023 | Cerevance | Series B | 0 |
9/2020 | Palleon Pharmaceuticals | Series B | 100M |
6/2022 | Code Biotherapeutics | Series A | 0 |
8/2018 | Ambys Medicines | Series A | 60M |
6/2016 | Ultragenyx Pharmaceutical | Post-IPO Equity | 65M |
11/2012 | ArmaGen Technologies | Series A | 0 |
3/2021 | StrideBio | Series B | 0 |
10/2018 | VelosBio | Series A | 58M |
10/2021 | Egle Therapeutics | Series A | 0 |
6/2021 | Transine Therapeutics | Seed Round | 0 |
10/2007 | CellCentric | Venture Round | 4.3M |
5/2018 | Cortexyme | Series B | 76M |
3/2020 | Redpin Therapeutics | Series A | 15.5M |
6/2011 | Redwood Bioscience | Venture Round | - |
12/2017 | Hookipa Pharma | Series C | 0 |
8/2016 | Bioniz Therapeutics | Series A | 0 |
5/2011 | Naurex | Series A | 18M |
6/2013 | Heptares Therapeutics | Series B | 0 |
10/2017 | Palleon Pharmaceuticals | Series A | 47.6M |
4/2005 | Receptor Biologix | Series A | 33.6M |
11/2020 | Catamaran Bio | Series A | 0 |
7/2018 | Presage Biosciences | Series D | 6M |
5/2023 | OncoResponse | Venture Round | 0 |
1/2023 | Ensoma | Series B | 0 |
5/2023 | Larkspur Biosciences | Series A | 0 |
10/2009 | Envoy Therapeutics | Series A | 8M |
1/2019 | Ribon Therapeutics | Series B | 65M |
8/2015 | Presage Biosciences | Venture Round | - |
4/2017 | Cortexyme | Debt Financing | 8M |
7/2018 | ARTham Therapeutics | Series A | - |
1/2018 | SEEDSUPPLY | Seed Round | - |
2/2022 | hC Bioscience | Series A | 0 |
2/2006 | Lectus Therapeutics | Series A | 14.3M |
1/2021 | Aspen RxHealth | Series B | 23M |
7/2020 | VelosBio | Series B | 137M |
3/2020 | Xilio Therapeutics | Series B | 100.5M |
7/2021 | Turnstone Biologics | Series D | 0 |
7/2004 | Serenex | Venture Round | 8M |
6/2021 | Ribon Therapeutics | Series C | 0 |
2/2018 | Wave Life Sciences | Post-IPO Equity | 60M |
12/2021 | Integra Therapeutics | Seed Round | 0 |
11/2019 | Avidity Biosciences | Series C | 0 |
8/2022 | Zelluna Immunotherapy | Venture Round | - |
12/2015 | Prosetta Biosciences | Series D | 31M |
11/2022 | Enzyre | Series A | 0 |
11/2018 | Axcelead | Seed Round | - |
9/2015 | Encycle Therapeutics | Venture Round | 0 |
2/2019 | BIOMx | Series B | 0 |
12/2017 | Obsidian Therapeutics | Series A | 0 |
5/2017 | GammaDelta Therapeutics | Venture Round | 100M |
3/2011 | CellCentric | Series B | - |
4/2022 | Be Biopharma | Series B | 0 |
5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
1/2006 | Symphogen | Series D | 0 |
4/2021 | Code Biotherapeutics | Seed Round | 0 |
1/2016 | Cortexyme | Series A | 15M |
4/2020 | Cerevance | Series B | 65M |
5/2023 | Larkspur Biosciences | Series A | 0 |
5/2023 | OncoResponse | Venture Round | 0 |
2/2023 | Cerevance | Series B | 0 |
1/2023 | Ensoma | Series B | 0 |
11/2022 | hC Bioscience | Series A | 0 |
11/2022 | Enzyre | Series A | 0 |
8/2022 | Zelluna Immunotherapy | Venture Round | - |
6/2022 | Code Biotherapeutics | Series A | 0 |
4/2022 | Be Biopharma | Series B | 0 |
2/2022 | hC Bioscience | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|